(下划线标示为目前在公司工作的研发人员)

1、蛋白激酶和HDAC双靶点抑制剂

Fan F, Liu P,  Bao R,  Chen L, Zhou M, Mo Z, Ma Y, Liu H, Zhou Y, Cai X,  Qian C, Liu X. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy, Cancer Res. 81:6233-45, 2021.

Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Forrester J, Zifcak B, Ma A, DellaRocca S, Borek M, Zhai HX, Cai X, Vio M. Cancer Network Disruption with a Single Molecule Targeting Histone Deacetylase Epigenatics and PI3K Pathway. Clin Cancer Res. 18: 4104-13, 2012.

Cai X, Qian C. Chapter 14 Discovery of HDAC-Inhibiting Multi-Target Inhibitors. In  Designing Multi-Target Drugs. RSC Publishing Editor(s): Morphy J. R, Harris C J. 221-242.

Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70:3647-56, 2010.

Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 53:2000-09, 2010.

2、Chaperone抑制剂

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 8:3296-06, 2009.

Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, Xu GX, Tao X, Zhai HX, Cai X, Qian C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 15:4046-57, 2009.

3、泛突变型EGFR抑制剂

Fan F,  Zhou M, Ye X,  Mo Z, Ma Y,  Luo L, Liang X, Liu H, Weng W, Lin M, Liu X, Cai X, Qian.  BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol 14:100961m 2021.

4、小核酸

Hao Liang,  Dalong Hou,  Siming Li,  Simin Chen,  Yaru Ma,  Haiqi Liu,  Fushun Fan,  Yuqiang Wang,  Changgeng Qian,  and Xinjian Liu*. Impurities from Hydroxyproline Derivatives in the Synthesis of Modified Oligonucleotides. Org. Process Res. Dev, 2024.9.22 online. DOI: 10.1021/acs.oprd.4c00295.